Skip to main content

12 Result(s)

within Tomoki Naoe Remove this filter English Remove this filter Cancer Research Remove this filter

and

  1. Article

    Open Access

    Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide

    We previously conducted a randomized phase II trial of OCV-501, a WT1 peptide presented by helper T cells, in elderly AML (acute myeloid leukemia) patients in first remission, indicating no difference in 2-yea...

    Tomoki Naoe, Akiko Saito, Nahoko Hosono, Senji Kasahara… in Cancer Immunology, Immunotherapy (2023)

    Download PDF (669 KB) View Article

  2. No Access

    Article

    Efficacy and safety of Wilms’ tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial

    Complete remission (CR) of acute myeloid leukemia (AML) in elderly patients has a short duration, and there is no suitable post-remission therapy. We explored the role of the Wilms’ tumor 1 helper peptide OCV-...

    Toru Kiguchi, Masaki Yamaguchi, Naoki Takezako… in Cancer Immunology, Immunotherapy (2022)

  3. Article

    Open Access

    Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

    Until recently, no effective targeted therapies for FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML) were available in Japan. The FLT3 inhibitor, gilteritinib, was approved in Japan ...

    Naoko Hosono, Hisayuki Yokoyama… in International Journal of Clinical Oncology (2021)

    Download PDF (1220 KB) View Article

  4. No Access

    Article

    Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study

    Between April 2004 and December 2010, we conducted a prospective randomized controlled study comparing tamibarotene with all-trans retinoic acid (ATRA) in the maintenance therapy of newly diagnosed acute promyelo...

    Akihiro Takeshita, Norio Asou, Yoshiko Atsuta, Toru Sakura, Yasunori Ueda… in Leukemia (2019)

  5. Article

    Correction: Corrigendum: Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults

    Nat. Genet. 48, 569–574 (2016); published online 28 March 2016; corrected after print 29 August 2016 In the version of this article initially published, the following statement was not included in the Online M...

    Takahiko Yasuda, Shinobu Tsuzuki, Masahito Kawazu, Fumihiko Hayakawa… in Nature Genetics (2016)

    Download PDF (104 KB) View Article

  6. No Access

    Article

    Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults

    Hiroyuki Mano and colleagues report fusions involving DUX4 in 16.4% of Ph-negative adolescent and young adult acute lymphoblastic leukemia (AYA-ALL) cases. Transplantation assays in mice support an oncogenic role...

    Takahiko Yasuda, Shinobu Tsuzuki, Masahito Kawazu, Fumihiko Hayakawa… in Nature Genetics (2016)

  7. No Access

    Article

    The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line

    Mantle cell lymphoma (MCL) is a B cell malignancy characterized by aberrant expression of cyclin D1 due to a t(11;14) translocation. MCL is refractory to conventional chemotherapy, and treatment remains challe...

    Kazumi Hagiwara, Shinji Kunishima, Hiroatsu Iida, Yasuhiko Miyata, Tomoki Naoe… in Apoptosis (2015)

  8. No Access

    Article

    Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia

    Nilotinib is a BCR-ABL kinase inhibitor approved for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (CML). The UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism UGT1A1*28 (*28)...

    Takashi Shibata, Yosuke Minami, Ayako Mitsuma… in International Journal of Clinical Oncology (2014)

  9. Article

    Open Access

    Identification of non-coding RNAs embracing microRNA-143/145 cluster

    In a variety of cancers, altered patterns of microRNA (miRNA) expression are reported and may affect the cell cycle and cell survival. Recent studies suggest that the expression level of miRNAs that act as tum...

    Akio Iio, Yoshihito Nakagawa, Ichiro Hirata, Tomoki Naoe, Yukihiro Akao in Molecular Cancer (2010)

    Download PDF (1145 KB) View Article

  10. No Access

    Article

    FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy

    Fusion gene products such as PML-RARα and BCR-ABL generated by leukemia-specific chromosomal translocations have been identified as target molecules for the treatment of leukemia. Here we describe one possibi...

    Tomoki Naoe, Hitoshi Kiyoi, Yukiya Yamamoto… in Cancer Chemotherapy and Pharmacology (2001)

  11. No Access

    Article

    Quality of life in adult patients after bone marrow transplantation

    Since culture, history, personal financial situation, and the health insurance system are strongly associated with quality of life (QOL) for patients undergoing continuing medical care, any investigation into ...

    Kunio Yano, Makoto Yazaki, Kenjiro Kitaori… in International Journal of Clinical Oncology (1998)

  12. No Access

    Article

    New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation

     All-trans retinoic acid (ATRA) is a potent differentiation drug for acute promyelocytic leukemia (APL) and is now incorporated into first-line therapy. However, ATRA resistance has become a major clinical proble...

    Kunio Kitamura, Hitoshi Kiyoi, Hitoshi Yoshida… in Cancer Chemotherapy and Pharmacology (1997)